Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature

被引:10
作者
John, Alexius [1 ,2 ]
Spain, Lavinia [2 ]
Hamid, Anis A. [1 ,2 ,3 ,4 ]
机构
[1] Eastern Hlth, Dept Med Oncol, Melbourne, Vic 3128, Australia
[2] Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic 3000, Australia
[3] Monash Univ, Eastern Hlth Clin Sch, Melbourne, Vic 3128, Australia
[4] Univ Melbourne, Dept Surg, Melbourne, Vic 3010, Australia
关键词
non-clear cell; renal cell carcinoma; papillary; hereditary leiomyomatosis and renal cell cancer; chromophobe; medullary; collecting duct; COMPREHENSIVE MOLECULAR CHARACTERIZATION; OPEN-LABEL; PHASE-II; SUNITINIB; CABOZANTINIB; EPIDEMIOLOGY; MULTICENTER; MONOTHERAPY; EXPRESSION; CRIZOTINIB;
D O I
10.3390/curroncol30010070
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Non-clear cell renal cell carcinoma (nccRCC) is an entity comprised of a heterogeneous constellation of RCC subtypes. Genomic profiling has broadened our understanding of molecular pathogenic mechanisms unique to individual nccRCC subtypes. To date, clinical trials evaluating the use of immunotherapies and targeted therapies have predominantly been conducted in patients with clear cell histology. A comprehensive review of the literature has been undertaken in order to describe molecular pathogenic mechanisms pertaining to each nccRCC subtype, and concisely summarise findings from therapeutic trials conducted in the nccRCC space.
引用
收藏
页码:923 / 937
页数:15
相关论文
共 88 条
  • [1] Treatment outcomes of metastatic nonclear cell renal cell carcinoma: A single institution retrospective analysis
    Agarwala, Vivek
    Ramaswamy, Anant
    Joshi, Amit
    Patil, Vijay Maruti
    Noronha, Vanita
    Menon, Santosh
    Popat, B. Palak
    Sable, Nilesh
    Prabhash, Kumar
    [J]. SOUTH ASIAN JOURNAL OF CANCER, 2018, 7 (04) : 226 - 230
  • [2] Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment Options
    Ahrens, Marit
    Scheich, Sebastian
    Hartmann, Arndt
    Bergmann, Lothar
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (03) : 128 - 135
  • [3] Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
    Albiges, Laurence
    Tannir, Nizar M.
    Burotto, Mauricio
    McDermott, David
    Plimack, Elizabeth R.
    Barthelemy, Philippe
    Porta, Camillo
    Powles, Thomas
    Donskov, Frede
    George, Saby
    Kollmannsberger, Christian K.
    Gurney, Howard
    Grimm, Marc-Oliver
    Tomita, Yoshihiko
    Castellano, Daniel
    Rini, Brian, I
    Choueiri, Toni K.
    Saggi, Shruti Shally
    McHenry, M. Brent
    Motzer, Robert J.
    [J]. ESMO OPEN, 2020, 5 (06)
  • [4] Everolimus versus sunitinib for patients with metastatic non-clear-cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial
    Armstrong, Andrew J.
    Halabi, Susan
    Eisen, Tim
    Broderick, Samuel
    Stadler, Walter M.
    Jones, Robert J.
    Garcia, Jorge A.
    Vaishampayan, Ulka N.
    Picus, Joel
    Hawkins, Robert E.
    Hainsworth, John D.
    Kollmannsberger, Christian K.
    Logan, Theodore F.
    Puzanov, Igor
    Pickering, Lisa M.
    Ryan, Christopher W.
    Protheroe, Andrew
    Lusk, Christine M.
    Oberg, Sadie
    George, Daniel J.
    [J]. LANCET ONCOLOGY, 2016, 17 (03) : 378 - 388
  • [5] Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)
    Atkins, Michael B.
    Jegede, Opeyemi A.
    Haas, Naomi B.
    McDermott, David F.
    Bilen, Mehmet A.
    Stein, Mark
    Sosman, Jeffrey A.
    Alter, Robert
    Plimack, Elizabeth R.
    Ornstein, Moshe
    Hurwitz, Michael
    Peace, David J.
    Signoretti, Sabina
    Denize, Thomas
    Cimadamore, Alessia
    Wu, Catherine J.
    Braun, David
    Einstein, David
    Catalano, Paul J.
    Hammers, Hans
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (25) : 2913 - +
  • [6] Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma
    Bakouny, Ziad
    Braun, David A.
    Shukla, Sachet A.
    Pan, Wenting
    Gao, Xin
    Hou, Yue
    Flaifel, Abdallah
    Tang, Stephen
    Bosma-Moody, Alice
    He, Meng Xiao
    Vokes, Natalie
    Nyman, Jackson
    Xie, Wanling
    Nassar, Amin H.
    Abou Alaiwi, Sarah
    Flippot, Ronan
    Bouchard, Gabrielle
    Steinharter, John A.
    Nuzzo, Pier Vitale
    Ficial, Miriam
    Sant'Angelo, Miriam
    Forman, Juliet
    Berchuck, Jacob E.
    Dudani, Shaan
    Bi, Kevin
    Park, Jihye
    Camp, Sabrina
    Sticco-Ivins, Maura
    Hirsch, Laure
    Baca, Sylvan C.
    Wind-Rotolo, Megan
    Ross-Macdonald, Petra
    Sun, Maxine
    Lee, Gwo-Shu Mary
    Chang, Steven L.
    Wei, Xiao X.
    McGregor, Bradley A.
    Harshman, Lauren C.
    Genovese, Giannicola
    Ellis, Leigh
    Pomerantz, Mark
    Hirsch, Michelle S.
    Freedman, Matthew L.
    Atkins, Michael B.
    Wu, Catherine J.
    Ho, Thai H.
    Linehan, W. Marston
    McDermott, David F.
    Heng, Daniel Y. C.
    Viswanathan, Srinivas R.
    [J]. NATURE COMMUNICATIONS, 2021, 12 (01)
  • [7] First-Line PAzopanib in NOn-clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study
    Buti, Sebastiano
    Bersanelli, Melissa
    Maines, Francesca
    Facchini, Gaetano
    Gelsomino, Francesco
    Zustovich, Fable
    Santoni, Matteo
    Verri, Elena
    De Giorgi, Ugo
    Masini, Cristina
    Morelli, Franco
    Vitale, Maria Giuseppa
    Sava, Teodoro
    Prati, Giuseppe
    Librici, Carmelinda
    Fraccon, Anna Paola
    Fornarini, Giuseppe
    Maruzzo, Marco
    Leonardi, Francesco
    Caffo, Orazio
    [J]. CLINICAL GENITOURINARY CANCER, 2017, 15 (04) : E609 - E614
  • [8] Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis
    Campbell, Matthew T.
    Bilen, Mehmet A.
    Shah, Amishi Y.
    Lemke, Emily
    Jonasch, E.
    Venkatesan, A. M.
    Altinmakas, E.
    Duran, C.
    Msaouel, Pavlos
    Tannir, N. M.
    [J]. EUROPEAN JOURNAL OF CANCER, 2018, 104 : 188 - 194
  • [9] Epidemiology of Renal Cell Carcinoma
    Capitanio, Umberto
    Bensalah, Karim
    Bex, Axel
    Boorjian, Stephen A.
    Bray, Freddie
    Coleman, Jonathan
    Gore, John L.
    Sun, Maxine
    Wood, Christopher
    Russo, Paul
    [J]. EUROPEAN UROLOGY, 2019, 75 (01) : 74 - 84
  • [10] Chromophobe Renal Cell Carcinoma: Results From a Large Single-Institution Series
    Casuscelli, Jozefina
    Becerra, Maria F.
    Seier, Kenneth
    Manley, Brandon J.
    Benfante, Nicole
    Redzematovic, Almedina
    Stief, Christian G.
    Hsieh, James J.
    Tickoo, Satish K.
    Reuter, Victor E.
    Coleman, Jonathan A.
    Russo, Paul
    Ostrovnaya, Irina
    Hakimi, A. Ari
    [J]. CLINICAL GENITOURINARY CANCER, 2019, 17 (05) : 373 - +